Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Cancer

Fig. 1

From: Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target

Fig. 1

Structure of Sulfasalazine (SSZ). SSZ is an amino-salicylate, specifically 5-((4- (2- Pyridylsulfamoyl) phenyl)azo) salicylic acid (systemic name: 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid), with a molecular mass of 398.394 g/mol. SSZ was developed in the 1950’s to treat rheumatoid arthritis and is also indicated for the use in ulcerative cholitis and Crohn’s disease. SSZ is commercially distributed under the brand names Azulfidine, Salazopyrin and Sulazine

Back to article page